Outlicensing
Vernalis is seeking to out-license or enter co-development arrangements for the following products:
V3381: dual NMDA antagonist/MAO-A inhibitor for neuropathic pain. Patient enrolment into the randomised phase of the V3381 (indantadol) Phase II IN-STEP study is now complete. The study, evaluating further the safety and efficacy of indantadol in patients with neuropathic pain due to diabetes, is being conducted at sites in the US, Canada, UK and Czech Republic. Headline data is expected around the end of the first quarter 2010. Worldwide rights available.
V85546: Phase II-ready novel selective anti-inflammatory compound that selectively inhibits MMP12 and has in-vivo efficacy in pre-clinical models of Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis (MS) and liver fibrosis. Phase I SAD and MAD studies have been conducted. Substantial safety and tox package would support up to 6 month dosing in Phase II. Worldwide rights available.
Frovatriptan: acute migraine treatment. Licensing rights available in territories outside North America, Central America, Europe and South Korea.
V10153: novel thrombolytic for stroke. Currently in Phase II studies. Worldwide rights available.
V1512: oral, soluble form of carbidopa-levodopa for motor complicated Parkinson’s disease patients. Ready for filing via 505(b)(2) in US, or equivalent in Europe. Worldwide rights (excluding Italy) available.
